Laboratory Corp of America Holdings (LH)

155.07
1.18 0.77
NYSE : Health Care
Prev Close 153.89
Open 154.71
Day Low/High 153.98 / 155.47
52 Wk Low/High 119.51 / 164.22
Volume 510.69K
Avg Volume 626.50K
Exchange NYSE
Shares Outstanding 101.80M
Market Cap 15.69B
EPS 7.10
P/E Ratio 21.59
Div & Yield N.A. (N.A)

Latest News

LabCorp Named Among

LabCorp Named Among "The World's Most Innovative Companies" In Forbes' 2017 Ranking

LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes' 2017 ranking of "The World's Most Innovative Companies.

LabCorp Is Scheduled To Present At The Morgan Stanley Global Healthcare Conference

LabCorp Is Scheduled To Present At The Morgan Stanley Global Healthcare Conference

LabCorp® (NYSE:LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference.

LabCorp Completes Acquisition Of Chiltern

LabCorp Completes Acquisition Of Chiltern

LabCorp® (NYSE: LH), a leading global life sciences company, has completed its previously announced acquisition of Chiltern, which will become part of the company's Covance Drug Development business.

The National Football League Alumni Association, Cancer Treatment Centers Of America® And LabCorp Team Up To Offer Prostate Cancer Screenings Starting In September

The National Football League Alumni Association, Cancer Treatment Centers Of America® And LabCorp Team Up To Offer Prostate Cancer Screenings Starting In September

Nearly one in seven men (one in five African-American men) will be diagnosed with prostate cancer in their lifetime

LabCorp's Acquisition Of Chiltern Clears Antitrust Review

LabCorp's Acquisition Of Chiltern Clears Antitrust Review

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the Federal Trade Commission had granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust...

LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer

LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that Dr.

LabCorp Prices $600,000,000 In 3.250% Senior Notes Due 2024 And $600,000,000 In 3.600% Senior Notes Due 2027

LabCorp Prices $600,000,000 In 3.250% Senior Notes Due 2024 And $600,000,000 In 3.600% Senior Notes Due 2027

LabCorp® (NYSE: LH) announced today that it has priced its offering of $1.

LabCorp Announces Proposed Sale Of Senior Notes

LabCorp Announces Proposed Sale Of Senior Notes

LabCorp® (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the "Notes").

Short Interest Decreases By 23.8% For LH

Short Interest Decreases By 23.8% For LH

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 630,218 share decrease in total short interest for Laboratory Corporation of America Holdings , to 2,022,387, a decrease of 23.76% since 07/14/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

LabCorp To Acquire Chiltern For Approximately $1.2 Billion In Cash, Advancing Its Leadership In Drug Development

LabCorp To Acquire Chiltern For Approximately $1.2 Billion In Cash, Advancing Its Leadership In Drug Development

LabCorp® (NYSE:LH), a leading global life sciences company, and Chiltern, a specialty CRO, announced today that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern's shareholders in an...

LabCorp Announces Record Results In The Second Quarter Of 2017 And Increases 2017 Guidance

LabCorp Announces Record Results In The Second Quarter Of 2017 And Increases 2017 Guidance

LabCorp ® (or the "Company") (NYSE: LH) today announced results for the second quarter ended June 30, 2017, and increased 2017 guidance.

LabCorp Introduces New ADAMTS13 Test For Rare Life-Threatening Blood Clot Disorder

LabCorp Introduces New ADAMTS13 Test For Rare Life-Threatening Blood Clot Disorder

LabCorp® (NYSE: LH) has begun offering its new, proprietary ADAMTS13 test to distinguish diseases characterized by life-threatening, acute thrombotic microangiopathy (TMA).

Bill Hanlon, Ph.D., Chief Development Officer And Head Of Global Regulatory Affairs, Covance (Photo: Business Wire)

Bill Hanlon, Ph.D., Chief Development Officer And Head Of Global Regulatory Affairs, Covance (Photo: Business Wire)

LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the National Evaluation System for health Technology Coordinating Center (NESTcc) has appointed William (Bill) Hanlon, Ph.

LabCorp And Novant Health Extend Laboratory Services Agreement

LabCorp And Novant Health Extend Laboratory Services Agreement

LabCorp® (NYSE: LH) and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

Walgreens And LabCorp Collaborate To Bring Patient Service Centers For Laboratory Testing To Select Walgreens Stores

Walgreens and LabCorp® (NYSE: LH) today announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores.

(Photo: Business Wire)

LabCorp® (NYSE:LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will extend its capabilities in precision medicine by opening a dedicated,...

Coalition For Access To Prenatal Screening Announces Clinical Advisory Board

Board to provide independent medical perspective on noninvasive prenatal screening

LabCorp Exclusively Launches Sera Prognostics' PreTRM Test To Assess For Risk Of Preterm Birth

LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test.

LabCorp Is Scheduled To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

LabCorp® (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2017 Health Care Conference.

LabCorp Completes Acquisition Of Pathology Associates Medical Laboratories

LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI).

LabCorp To Webcast Its Annual Meeting Of Shareholders

LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, 2017 at 9:00 a.

LabCorp Enhances VistaSeq Hereditary Cancer Test Portfolio With Addition Of New Panels And New Genes That Can Be Assessed

LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeq SM Hereditary Cancer portfolio, with ten new test panels focusing on the risk of specific hereditary cancer syndromes.

LabCorp's Acquisition Of Pathology Associates Medical Laboratories Clears Antitrust Review

LabCorp® (NYSE: LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp's acquisition of Pathology Associates Medical Laboratories,...

LabCorp Completes Acquisition Of Assets Of Mount Sinai Health System Clinical Outreach Laboratories

LabCorp ® (NYSE: LH), a leading global life sciences company, has completed the previously announced acquisition of assets of the Mount Sinai Health System Clinical Outreach Laboratories.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

LabCorp To Exclusively Offer The M3 Checklist, A Multi-Condition Mental Health Screening Tool

LabCorp ® (NYSE:LH) and M-3 Information, LLC today announced the nationwide availability through LabCorp of the peer-reviewed, clinically validated M3 Checklist assessment for mental illness.

Laboratory Corporation Of America® Holdings Announces 2017 First Quarter Results And Updates 2017 Guidance

Laboratory Corporation of America ® Holdings (LabCorp ® or the "Company") (NYSE: LH) today announced results for the first quarter ended March 31, 2017, and updated 2017 guidance.

TheStreet Quant Rating: A (Buy)